(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are PAVmed, GameStop, and Passage Bio.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | PAVmed (PAVMW) | 0.03 | 105.67% | 2023-11-28 22:44:05 |
| 2 | GameStop (GME) | 16.67 | 23.57% | 2023-11-29 12:55:22 |
| 3 | Passage Bio (PASG) | 0.73 | 17.7% | 2023-11-28 22:41:06 |
| 4 | FibroGen (FGEN) | 0.54 | 17.47% | 2023-11-29 12:12:17 |
| 5 | NetApp (NTAP) | 89.91 | 15.11% | 2023-11-29 12:50:48 |
| 6 | Workday (WDAY) | 267.10 | 12.54% | 2023-11-29 12:52:03 |
| 7 | QuantumScape (QS) | 6.43 | 12.3% | 2023-11-29 13:01:16 |
| 8 | CrowdStrike Holdings (CRWD) | 232.96 | 9.71% | 2023-11-29 12:51:31 |
| 9 | General Motors (GM) | 31.67 | 9.64% | 2023-11-29 12:55:20 |
| 10 | Oportun Financial Corporation (OPRT) | 2.42 | 9.01% | 2023-11-28 19:41:05 |
The three biggest losers today are PAVmed, Orgenesis, and Bilibili.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | PAVmed (PAVMZ) | 0.06 | -27.63% | 2023-11-28 22:55:27 |
| 2 | Orgenesis (ORGS) | 0.44 | -11.96% | 2023-11-28 19:44:06 |
| 3 | Bilibili (BILI) | 12.08 | -9.48% | 2023-11-29 12:51:25 |
| 4 | Puma Biotechnology (PBYI) | 4.10 | -8.69% | 2023-11-28 23:09:06 |
| 5 | Personalis (PSNL) | 1.65 | -8.33% | 2023-11-29 05:12:05 |
| 6 | Profound Medical Corp. (PROF) | 10.21 | -6.76% | 2023-11-29 04:42:06 |
| 7 | Spectra Energy (SE) | 37.11 | -6.57% | 2023-11-29 12:58:50 |
| 8 | Ovid Therapeutics (OVID) | 3.03 | -6.19% | 2023-11-28 21:10:06 |
| 9 | Zai Lab (ZLAB) | 26.54 | -5.25% | 2023-11-29 12:52:06 |
| 10 | PainReform Ltd. (PRFX) | 2.23 | -5.11% | 2023-11-29 04:23:06 |
Winners today
1. PAVmed (PAVMW) – 105.67%
NASDAQ ended the session with PAVmed jumping 105.67% to $0.03 on Thursday, after five consecutive sessions in a row of losses. NASDAQ fell 0.16% to $14,258.49, following the last session’s upward trend on what was a somewhat down trend trading session today.
Moving Average
PAVmed’s value is way under its 50-day moving average of $0.21 and way below its 200-day moving average of $1.66.
Yearly Top and Bottom Value
PAVmed’s stock is valued at $0.03 at 01:32 EST, way below its 52-week high of $4.74 and way above its 52-week low of $0.02.
Volume
Today’s last reported volume for PAVmed is 32626 which is 397.12% above its average volume of 6563.
More news about PAVmed.
2. GameStop (GME) – 23.57%
GameStop Corp., a specialty retailer, provides games and entertainment products through its stores and ecommerce platforms in the United States, Canada, Australia, and Europe. The company sells new and pre-owned gaming platforms; accessories, such as controllers, gaming headsets, and virtual reality products; new and pre-owned gaming software; and in-game digital currency, digital downloadable content, and full-game downloads. It also sells collectibles comprising apparel, toys, trading cards, gadgets, and other retail products for pop culture and technology enthusiasts, as well as engages in the digital asset wallet and NFT marketplace activities. The company operates stores and ecommerce sites under the GameStop, EB Games, and Micromania brands; and pop culture themed stores that sell collectibles, apparel, gadgets, electronics, toys, and other retail products under the Zing Pop Culture brand, as well as offers Game Informer magazine, a print and digital gaming publication. The company was formerly known as GSC Holdings Corp. GameStop Corp. was founded in 1996 and is headquartered in Grapevine, Texas.
NYSE ended the session with GameStop rising 23.57% to $16.67 on Thursday while NYSE jumped 0.2% to $15,960.22.
Earnings Per Share
As for profitability, GameStop has a trailing twelve months EPS of $-0.32.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -7.64%.
Volatility
GameStop’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.59%, a negative 0.48%, and a positive 2.90%.
GameStop’s highest amplitude of average volatility was 1.59% (last week), 3.29% (last month), and 2.90% (last quarter).
Sales Growth
GameStop’s sales growth for the next quarter is negative 1.3%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 74.2% and 43.8%, respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GameStop’s stock is considered to be overbought (>=80).
Previous days news about GameStop
- Gamestop stock’s best day since January driven by fresh wave of speculative bets. According to MarketWatch on Tuesday, 28 November, "Traders are piling into long-shot GameStop Inc. call options that would pay off if the stock price nearly doubles before, or shortly after, the company’s Dec. 6 earnings report, FactSet data show."
- : gamestop stock soars toward biggest 2-day gain 9 months. According to MarketWatch on Wednesday, 29 November, "Shares of GameStop Corp. ran up 15.4% toward a seven-week high, as the original "meme" stock continued to get a boost from has gained 1.7%."
More news about GameStop.
3. Passage Bio (PASG) – 17.7%
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
NASDAQ ended the session with Passage Bio rising 17.7% to $0.73 on Thursday, following the last session’s upward trend. NASDAQ dropped 0.16% to $14,258.49, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, Passage Bio has a trailing twelve months EPS of $-2.05.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -64.09%.
More news about Passage Bio.
4. FibroGen (FGEN) – 17.47%
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
NASDAQ ended the session with FibroGen rising 17.47% to $0.54 on Thursday, following the last session’s upward trend. NASDAQ fell 0.16% to $14,258.49, following the last session’s upward trend on what was a somewhat bearish trend exchanging session today.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FibroGen’s stock is considered to be overbought (>=80).
More news about FibroGen.
5. NetApp (NTAP) – 15.11%
NetApp, Inc. provides cloud-led and data-centric services to manage and share data on-premises, and private and public clouds worldwide. It operates in two segments, Hybrid Cloud and Public Could. The company offers intelligent data management software, such as NetApp ONTAP, NetApp Snapshot, NetApp SnapCenter Backup Management, NetApp SnapMirror Data Replication, NetApp SnapLock Data Compliance, and storage infrastructure solutions, including NetApp All-Flash FAS series, NetApp Fabric Attached Storage, NetApp E/EF series, and NetApp StorageGRID. In addition, it provides cloud storage and data services comprising NetApp Cloud Volumes ONTAP, Azure NetApp Files, Amazon FSx for NetApp ONTAP, NetApp Cloud Volumes Service for Google Cloud, and cloud operations services, such as NetApp Cloud Insights, Spot by NetApp, and Instaclustr. Further, the company offers application-aware data management service under the NetApp Astra name; and professional and support services, such as strategic consulting, professional, managed, and support services. Additionally, it provides assessment, design, implementation, and migration services. The company serves the energy, financial service, government, technology, internet, life science, healthcare service, manufacturing, media, entertainment, animation, video postproduction, and markets through a direct sales force and an ecosystem of partners. NetApp, Inc. was incorporated in 1992 and is headquartered in San Jose, California.
NASDAQ ended the session with NetApp rising 15.11% to $89.91 on Thursday while NASDAQ dropped 0.16% to $14,258.49.
Earnings Per Share
As for profitability, NetApp has a trailing twelve months EPS of $5.52.
PE Ratio
NetApp has a trailing twelve months price to earnings ratio of 16.29. Meaning, the purchaser of the share is investing $16.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 158.04%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 10.1%, now sitting on 6.2B for the twelve trailing months.
Moving Average
NetApp’s worth is way above its 50-day moving average of $75.63 and way higher than its 200-day moving average of $71.56.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NetApp’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for NetApp is 5447130 which is 246.27% above its average volume of 1573050.
Previous days news about NetApp
- : netapp stock rallies on upbeat full-year outlook. According to MarketWatch on Tuesday, 28 November, "Shares of NetApp Inc. NTAP jumped 9.7% after hours on Tuesday after the data and storage software company forecast more upbeat profit and sales trends for its full fiscal year. "
- Here's what key metrics tell us about netapp (ntap) Q2 earnings. According to Zacks on Tuesday, 28 November, "For the quarter ended October 2023, NetApp (NTAP Quick QuoteNTAP – Free Report) reported revenue of $1.56 billion, down 6.1% over the same period last year. ", "Here is how NetApp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
More news about NetApp.
6. Workday (WDAY) – 12.54%
Workday, Inc. provides enterprise cloud applications in the United States and internationally. Its applications help its customers to plan, execute, analyze, and extend to other applications and environments, and to manage their business and operations. The company offers a suite of financial management applications, which enable chief financial officers to maintain accounting information in the general ledger; manage financial processes, such as payables and receivables; identify real-time financial, operational, and management insights; enhance financial consolidation; reduce time-to-close; promote internal control and auditability; and achieve consistency across finance operations. It also provides spend management solutions that helps organizations to streamline supplier selection and contracts, manage indirect spend, and build and execute sourcing events, such as requests for proposals; and human capital management solution, a suite of human capital management applications that allows organizations to manage the entire employee lifecycle from recruitment to retirement, and enables HR teams to hire, onboard, pay, develop, reskill, and provide employee experiences. In addition, the company offers applications for planning; and applications for analytics and reporting comprising augmented analytics to surface insights to the line of business in simple-to-understand stories, machine learning to drive efficiency and automation, and benchmarks to compare performance against other companies. It serves professional and business services, financial services, healthcare, education, government, technology, media, retail, and hospitality industries. The company has a partnership with Accenture to develop a suite of data-led and composable finance solutions. The company was formerly known as North Tahoe Power Tools, Inc. and changed its name to Workday, Inc. in July 2005. Workday, Inc. was incorporated in 2005 and is headquartered in Pleasanton, California.
NASDAQ ended the session with Workday jumping 12.54% to $267.10 on Thursday, following the last session’s upward trend. NASDAQ fell 0.16% to $14,258.49, following the last session’s upward trend on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, Workday has a trailing twelve months EPS of $0.24.
PE Ratio
Workday has a trailing twelve months price to earnings ratio of 1112.92. Meaning, the purchaser of the share is investing $1112.92 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -2.13%.
Yearly Top and Bottom Value
Workday’s stock is valued at $267.10 at 01:32 EST, above its 52-week high of $252.72.
Volatility
Workday’s last week, last month’s, and last quarter’s current intraday variation average was 0.34%, 0.68%, and 1.29%.
Workday’s highest amplitude of average volatility was 0.67% (last week), 1.06% (last month), and 1.29% (last quarter).
Previous days news about Workday
- Workday (wday) Q3 earnings: how key metrics compare to wall street estimates. According to Zacks on Tuesday, 28 November, "For the quarter ended October 2023, Workday (WDAY Quick QuoteWDAY – Free Report) reported revenue of $1.87 billion, up 16.7% over the same period last year. ", "Here is how Workday performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
More news about Workday.
7. QuantumScape (QS) – 12.3%
QuantumScape Corporation, a development stage company, focuses on the development and commercialization of solid-state lithium-metal batteries for electric vehicles and other applications. QuantumScape Corporation was founded in 2010 and is headquartered in San Jose, California.
NYSE ended the session with QuantumScape jumping 12.3% to $6.43 on Thursday while NYSE jumped 0.2% to $15,960.22.
Earnings Per Share
As for profitability, QuantumScape has a trailing twelve months EPS of $-0.98.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31.48%.
Volume
Today’s last reported volume for QuantumScape is 15215300 which is 211.99% above its average volume of 4876820.
Moving Average
QuantumScape’s worth is higher than its 50-day moving average of $6.17 and way below its 200-day moving average of $7.46.
More news about QuantumScape.
8. CrowdStrike Holdings (CRWD) – 9.71%
CrowdStrike Holdings, Inc. provides cloud-delivered protection across endpoints and cloud workloads, identity, and data. It offers corporate workload security, security and vulnerability management, managed security services, IT operations management, threat intelligence services, identity protection, and log management. The company primarily sells subscriptions to its Falcon platform and cloud modules through its direct sales team that leverages its network of channel partners. It serves customers worldwide. The company was incorporated in 2011 and is headquartered in Austin, Texas.
NASDAQ ended the session with CrowdStrike Holdings rising 9.71% to $232.96 on Thursday, following the last session’s upward trend. NASDAQ slid 0.16% to $14,258.49, following the last session’s upward trend on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, CrowdStrike Holdings has a trailing twelve months EPS of $-0.4.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.08%.
Yearly Top and Bottom Value
CrowdStrike Holdings’s stock is valued at $232.96 at 01:32 EST, higher than its 52-week high of $212.86.
Sales Growth
CrowdStrike Holdings’s sales growth for the next quarter is 31.3%.
More news about CrowdStrike Holdings.
9. General Motors (GM) – 9.64%
General Motors Company designs, builds, and sells trucks, crossovers, cars, and automobile parts; and provide software-enabled services and subscriptions worldwide. The company operates through GM North America, GM International, Cruise, and GM Financial segments. It markets its vehicles primarily under the Buick, Cadillac, Chevrolet, GMC, Baojun, and Wuling brand names. The company also sells trucks, crossovers, cars, and automobile parts through retail dealers, and distributors and dealers, as well as to fleet customers, including daily rental car companies, commercial fleet customers, leasing companies, and governments. In addition, it offers range of after-sale services through dealer network, such as maintenance, light repairs, collision repairs, vehicle accessories, and extended service warranties; and safety and security services for retail and fleet customers, including automatic crash response, emergency services, roadside assistance, crisis assist, stolen vehicle assistance, and turn-by-turn navigation. Further, the company provides connected services comprising mobile applications for owners to remotely control their vehicles and electric vehicle owners to locate charging stations, on-demand vehicle diagnostics, GM Smart Driver, Amazon Alexa in-vehicle voice, Google's Voice Assistant, navigation and app ecosystem, connected navigation, SiriusXM with 360L, and 4G LTE wireless connectivity. Additionally, the company provides automotive financing and insurance services; and software-enabled services and subscriptions. General Motors Company was founded in 1908 and is headquartered in Detroit, Michigan.
NYSE ended the session with General Motors jumping 9.64% to $31.67 on Thursday, after four sequential sessions in a row of gains. NYSE jumped 0.2% to $15,960.22, after two sequential sessions in a row of losses, on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, General Motors has a trailing twelve months EPS of $7.12.
PE Ratio
General Motors has a trailing twelve months price to earnings ratio of 4.45. Meaning, the purchaser of the share is investing $4.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.27%.
Yearly Top and Bottom Value
General Motors’s stock is valued at $31.67 at 01:32 EST, way under its 52-week high of $43.63 and way higher than its 52-week low of $26.30.
Moving Average
General Motors’s worth is above its 50-day moving average of $29.93 and below its 200-day moving average of $34.43.
More news about General Motors.
10. Oportun Financial Corporation (OPRT) – 9.01%
Oportun Financial Corporation provides financial services. It offers personal loans and credit cards. The company serves customers through online and over-the-phone, as well as through retail and Lending as a Service partner locations. Oportun Financial Corporation was founded in 2005 and is headquartered in San Carlos, California.
NASDAQ ended the session with Oportun Financial Corporation rising 9.01% to $2.42 on Thursday while NASDAQ fell 0.16% to $14,258.49.
Earnings Per Share
As for profitability, Oportun Financial Corporation has a trailing twelve months EPS of $-4.05.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -29.59%.
Sales Growth
Oportun Financial Corporation’s sales growth is 0.9% for the ongoing quarter and 5.9% for the next.
Volume
Today’s last reported volume for Oportun Financial Corporation is 335432 which is 34.84% above its average volume of 248749.
More news about Oportun Financial Corporation.
Losers Today
1. PAVmed (PAVMZ) – -27.63%
NASDAQ ended the session with PAVmed falling 27.63% to $0.06 on Thursday, after five consecutive sessions in a row of losses. NASDAQ slid 0.16% to $14,258.49, following the last session’s upward trend on what was a somewhat down trend trading session today.
Yearly Top and Bottom Value
PAVmed’s stock is valued at $0.06 at 01:32 EST, way under its 52-week high of $0.07 and above its 52-week low of $0.06.
More news about PAVmed.
2. Orgenesis (ORGS) – -11.96%
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
NASDAQ ended the session with Orgenesis sliding 11.96% to $0.44 on Thursday, after four consecutive sessions in a row of losses. NASDAQ slid 0.16% to $14,258.49, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, Orgenesis has a trailing twelve months EPS of $-0.91.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -102.45%.
Sales Growth
Orgenesis’s sales growth is 40.9% for the present quarter and 70.4% for the next.
Moving Average
Orgenesis’s worth is way below its 50-day moving average of $0.71 and way under its 200-day moving average of $1.07.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Orgenesis’s EBITDA is 1.36.
More news about Orgenesis.
3. Bilibili (BILI) – -9.48%
Bilibili Inc. provides online entertainment services for the young generations in the People's Republic of China. Its platform offers a range of content, including video services, mobile games, and value-added service, as well as ACG-related comic and audio content. The company's video services include professional user generated videos, occupationally generated videos, live broadcasting, and story mode. Bilibili Inc. was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.
NASDAQ ended the session with Bilibili falling 9.48% to $12.08 on Thursday, after two consecutive sessions in a row of losses. NASDAQ dropped 0.16% to $14,258.49, following the last session’s upward trend on what was a somewhat down trend trading session today.
Earnings Per Share
As for profitability, Bilibili has a trailing twelve months EPS of $-1.88.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31.27%.
More news about Bilibili.
4. Puma Biotechnology (PBYI) – -8.69%
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral), for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib, intravenous), and PB357. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
NASDAQ ended the session with Puma Biotechnology dropping 8.69% to $4.10 on Thursday while NASDAQ dropped 0.16% to $14,258.49.
Earnings Per Share
As for profitability, Puma Biotechnology has a trailing twelve months EPS of $0.07.
PE Ratio
Puma Biotechnology has a trailing twelve months price to earnings ratio of 58.57. Meaning, the purchaser of the share is investing $58.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.21%.
Moving Average
Puma Biotechnology’s worth is way above its 50-day moving average of $2.89 and way above its 200-day moving average of $3.18.
Yearly Top and Bottom Value
Puma Biotechnology’s stock is valued at $4.10 at 01:32 EST, way under its 52-week high of $5.16 and way higher than its 52-week low of $2.13.
More news about Puma Biotechnology.
5. Personalis (PSNL) – -8.33%
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
NASDAQ ended the session with Personalis falling 8.33% to $1.65 on Thursday while NASDAQ slid 0.16% to $14,258.49.
Earnings Per Share
As for profitability, Personalis has a trailing twelve months EPS of $-2.38.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -57.31%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 25.4% and 18%, respectively.
Sales Growth
Personalis’s sales growth is 17.3% for the current quarter and 0.4% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22.8%, now sitting on 70.53M for the twelve trailing months.
Volume
Today’s last reported volume for Personalis is 916043 which is 117.3% above its average volume of 421553.
More news about Personalis.
6. Profound Medical Corp. (PROF) – -6.76%
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
NASDAQ ended the session with Profound Medical Corp. sliding 6.76% to $10.21 on Thursday, after two consecutive sessions in a row of losses. NASDAQ fell 0.16% to $14,258.49, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, Profound Medical Corp. has a trailing twelve months EPS of $-1.39.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.15%.
More news about Profound Medical Corp..
7. Spectra Energy (SE) – -6.57%
Sea Limited, together with its subsidiaries, engages in the digital entertainment, e-commerce, and digital financial service businesses in Southeast Asia, Latin America, rest of Asia, and internationally. It offers Garena digital entertainment platform for users to access mobile and PC online games, as well as eSports operations. The company also operates Shopee e-commerce platform, a mobile-centric marketplace that provides integrated payment and logistics infrastructure and seller services. In addition, it offers SeaMoney digital financial services to individuals and businesses, including offline and online mobile wallet, and payment processing services, as well as other offerings across credit, insurtech, and digital bank services under the ShopeePay, SPayLater, SeaBank, SeaInsure, and other digital financial services brands; and payment processing services for Shopee. The company was formerly known as Garena Interactive Holding Limited and changed its name to Sea Limited in April 2017. Sea Limited was incorporated in 2009 and is headquartered in Singapore.
NYSE ended the session with Spectra Energy falling 6.57% to $37.11 on Thursday while NYSE rose 0.2% to $15,960.22.
Earnings Per Share
As for profitability, Spectra Energy has a trailing twelve months EPS of $1.21.
PE Ratio
Spectra Energy has a trailing twelve months price to earnings ratio of 30.67. Meaning, the purchaser of the share is investing $30.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.09%.
Volatility
Spectra Energy’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.04%, a negative 0.46%, and a positive 2.80%.
Spectra Energy’s highest amplitude of average volatility was 3.04% (last week), 3.79% (last month), and 2.80% (last quarter).
Sales Growth
Spectra Energy’s sales growth is negative 0.9% for the present quarter and 7.9% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 156.9% and a negative 460%, respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Spectra Energy’s stock is considered to be oversold (<=20).
More news about Spectra Energy.
8. Ovid Therapeutics (OVID) – -6.19%
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, currently under preclinical stage, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825, currently under preclinical stage, which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, currently under preclinical stage, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
NASDAQ ended the session with Ovid Therapeutics sliding 6.19% to $3.03 on Thursday while NASDAQ slid 0.16% to $14,258.49.
Earnings Per Share
As for profitability, Ovid Therapeutics has a trailing twelve months EPS of $-0.68.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.88%.
Volume
Today’s last reported volume for Ovid Therapeutics is 99327 which is 15.68% below its average volume of 117809.
Sales Growth
Ovid Therapeutics’s sales growth is 30.4% for the ongoing quarter and 21.2% for the next.
Moving Average
Ovid Therapeutics’s value is way under its 50-day moving average of $3.54 and under its 200-day moving average of $3.30.
More news about Ovid Therapeutics.
9. Zai Lab (ZLAB) – -5.25%
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.
NASDAQ ended the session with Zai Lab dropping 5.25% to $26.54 on Thursday while NASDAQ slid 0.16% to $14,258.49.
Earnings Per Share
As for profitability, Zai Lab has a trailing twelve months EPS of $-3.1.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -30.29%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Zai Lab’s stock is considered to be overbought (>=80).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Zai Lab’s EBITDA is 7.46.
More news about Zai Lab.
10. PainReform Ltd. (PRFX) – -5.11%
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
NASDAQ ended the session with PainReform Ltd. dropping 5.11% to $2.23 on Thursday while NASDAQ slid 0.16% to $14,258.49.
Earnings Per Share
As for profitability, PainReform Ltd. has a trailing twelve months EPS of $-6.64.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.08%.
More news about PainReform Ltd..
Stay up to date with our winners and losers daily report
